259 related articles for article (PubMed ID: 11675905)
1. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
Schaberg T; Ballin I; Huchon G; Bassaris H; Hampel B; Reimnitz P;
J Int Med Res; 2001; 29(4):314-28. PubMed ID: 11675905
[TBL] [Abstract][Full Text] [Related]
2. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis.
Read RC; Kuss A; Berrisoul F; Kearsley N; Torres A; Kubin R
Respir Med; 1999 Apr; 93(4):252-61. PubMed ID: 10464889
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
[TBL] [Abstract][Full Text] [Related]
7. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
Hoepelman IM; Möllers MJ; van Schie MH; Greefhorst AP; Schlösser NJ; Sinninghe Damsté EJ; van de Moosdijk CN; Dalinghaus WH; Eland ME; Mol SJ; Rozenberg-Arska M
Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
[TBL] [Abstract][Full Text] [Related]
8. Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.
Solèr M; Lode H; Baldwin R; Levine JH; Schreurs AJ; van Noord JA; Maesen FP; Zehrer M;
Eur J Clin Microbiol Infect Dis; 2003 Mar; 22(3):144-50. PubMed ID: 12649711
[TBL] [Abstract][Full Text] [Related]
9. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.
Wilson R; Kubin R; Ballin I; Deppermann KM; Bassaris HP; Leophonte P; Schreurs AJ; Torres A; Sommerauer B
J Antimicrob Chemother; 1999 Oct; 44(4):501-13. PubMed ID: 10588312
[TBL] [Abstract][Full Text] [Related]
10. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Chodosh S; DeAbate CA; Haverstock D; Aneiro L; Church D
Respir Med; 2000 Jan; 94(1):18-27. PubMed ID: 10714475
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group.
Siegert R; Gehanno P; Nikolaidis P; Bagger-Sjöbäck D; Ibanez JM; Hampel B; Sommerauer B
Respir Med; 2000 Apr; 94(4):337-44. PubMed ID: 10845431
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis.
Anzueto A; Fisher CL; Busman T; Olson CA
Clin Ther; 2001 Jan; 23(1):72-86. PubMed ID: 11219481
[TBL] [Abstract][Full Text] [Related]
15. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.
Schaberg T; Möller M; File T; Stauch K; Landen H
Clin Drug Investig; 2006; 26(12):733-44. PubMed ID: 17274680
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis.
McAdoo MA; Rice K; Gordon GR; Sahn SA
Clin Ther; 1998; 20(1):88-100. PubMed ID: 9522107
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
Sethi S; Breton J; Wynne B
Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
